A
12.33
-0.14 (-1.08%)
| Penutupan Terdahulu | 12.46 |
| Buka | 12.50 |
| Jumlah Dagangan | 910,296 |
| Purata Dagangan (3B) | 1,727,223 |
| Modal Pasaran | 1,314,676,096 |
| Harga / Jualan (P/S) | 0.660 |
| Harga / Buku (P/B) | 4.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Operasi (TTM) | 16,317.06% |
| EPS Cair (TTM) | -3.10 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.69% |
| Nisbah Semasa (MRQ) | 12.05 |
| Aliran Tunai Operasi (OCF TTM) | -206.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -182.62 M |
| Pulangan Atas Aset (ROA TTM) | -40.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -83.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Amylyx Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.40 |
|
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.54% |
| % Dimiliki oleh Institusi | 85.89% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Guggenheim, 102.84%) | Beli |
| Median | 20.00 (62.27%) | |
| Rendah | 16.00 (B of A Securities, 29.82%) | Beli |
| Purata | 20.00 (62.27%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 13.28 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 20.00 (62.27%) | Beli | 12.31 |
| Citigroup | 17 Oct 2025 | 20.00 (62.27%) | Beli | 14.95 |
| Baird | 16 Oct 2025 | 19.00 (54.16%) | Beli | 15.17 |
| B of A Securities | 03 Oct 2025 | 16.00 (29.82%) | Beli | 13.42 |
| Goldman Sachs | 16 Sep 2025 | 20.00 (62.27%) | Beli | 11.96 |
| Guggenheim | 15 Sep 2025 | 25.00 (102.84%) | Beli | 11.85 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BEDROSIAN CAMILLE L | - | 14.24 | -6,580 | -93,699 |
| Jumlah Keseluruhan Kuantiti Bersih | -6,580 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -93,699 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 14.24 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BEDROSIAN CAMILLE L | Pegawai | 01 Dec 2025 | Jual (-) | 6,580 | 14.24 | 93,699 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Dec 2025 | Pengumuman | Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial |
| 06 Nov 2025 | Pengumuman | Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences |
| 30 Oct 2025 | Pengumuman | Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 |
| 10 Sep 2025 | Pengumuman | Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock |
| 09 Sep 2025 | Pengumuman | Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |